Met Life Investment Management, LLC Nuvation Bio Inc. Transaction History

Met Life Investment Management, LLC

$17.1 Billion
Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 91,051 shares of NUVB stock, worth $256,763. This represents 0.0% of its overall portfolio holdings.

Number of Shares

91,051

Previous 105,678 13.84%

Holding current value

$256,763

Previous $308,000 32.14%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$2.3 - $3.83 $33,642 - $56,021	-14,627 Reduced 13.84%	91,051 $209,000
Q2 2024 Aug 13, 2024	BUY	$2.58 - $3.69 $52,340 - $74,859	20,287 Added 23.76%	105,678 $308,000
Q1 2024 May 14, 2024	BUY	$1.46 - $3.97 $124,670 - $339,002	85,391 New	85,391 $310,000
Q3 2023 May 09, 2024	BUY	$1.26 - $2.1 $16,374 - $27,291	12,996 Added 19.6%	79,288 $106,000
Q2 2023 Apr 29, 2024	BUY	$1.56 - $1.84 $123,689 - $145,889	79,288 New	79,288 $142,000
Q2 2023 Aug 10, 2023	BUY	$1.56 - $1.84 $20,273 - $23,912	12,996 Added 19.6%	79,288 $142,000
Q1 2023 May 09, 2024	BUY	$1.6 - $2.48 $106,067 - $164,404	66,292 New	66,292 $110 Million
Q1 2023 May 15, 2023	BUY	$1.6 - $2.48 $37,606 - $58,289	23,504 Added 54.93%	66,292 $110,000
Q4 2022 May 10, 2024	SELL	$1.68 - $2.5 $37,045 - $55,127	-22,051 Reduced 34.01%	42,788 $82,000
Q4 2022 Jun 14, 2023	SELL	$1.68 - $2.5 $39,486 - $58,760	-23,504 Reduced 35.46%	42,788 $82,000
Q4 2022 Mar 22, 2023	SELL	$1.68 - $2.5 $37,045 - $55,127	-22,051 Reduced 34.01%	42,788 $82,000
Q4 2022 Feb 15, 2023	SELL	$1.68 - $2.5 $37,045 - $55,127	-22,051 Reduced 34.01%	42,788 $82,000
Q3 2022 Jun 14, 2023	SELL	$0.29 - $4.04 $421 - $5,870	-1,453 Reduced 2.19%	64,839 $145,000
Q2 2022 May 10, 2024	SELL	$3.24 - $5.85 $80,468 - $145,290	-24,836 Reduced 27.7%	64,839 $210,000
Q2 2022 Jun 20, 2023	SELL	$3.24 - $5.85 $4,707 - $8,500	-1,453 Reduced 2.19%	64,839 $210,000
Q2 2022 Mar 22, 2023	SELL	$3.24 - $5.85 $80,468 - $145,290	-24,836 Reduced 27.7%	64,839 $210,000
Q2 2022 Aug 11, 2022	SELL	$3.24 - $5.85 $80,468 - $145,290	-24,836 Reduced 27.7%	64,839 $210,000
Q1 2022 May 10, 2024	BUY	$4.6 - $8.83 $412,504 - $791,830	89,675 New	89,675 $471,000
Q1 2022 Jun 20, 2023	BUY	$4.6 - $8.83 $107,561 - $206,471	23,383 Added 35.27%	89,675 $471,000
Q1 2022 Mar 22, 2023	BUY	$4.6 - $8.83 $147,085 - $282,339	31,975 Added 55.42%	89,675 $471,000
Q1 2022 May 12, 2022	BUY	$4.6 - $8.83 $147,085 - $282,339	31,975 Added 55.42%	89,675 $472,000
Q4 2021 May 17, 2024	BUY	$7.75 - $10.05 $249,154 - $323,097	32,149 Added 125.82%	57,700 $490,000
Q4 2021 Jun 21, 2023	SELL	$7.75 - $10.05 $66,588 - $86,349	-8,592 Reduced 12.96%	57,700 $490,000
Q4 2021 Mar 22, 2023	BUY	$7.75 - $10.05 $249,154 - $323,097	32,149 Added 125.82%	57,700 $490,000
Q4 2021 Feb 15, 2022	BUY	$7.75 - $10.05 $249,154 - $323,097	32,149 Added 125.82%	57,700 $490,000
Q3 2021 May 17, 2024	BUY	$7.78 - $10.0 $66,573 - $85,570	8,557 Added 50.35%	25,551 $253,000
Q3 2021 Jun 21, 2023	SELL	$7.78 - $10.0 $316,964 - $407,410	-40,741 Reduced 61.46%	25,551 $253,000
Q3 2021 Mar 22, 2023	BUY	$7.78 - $10.0 $66,573 - $85,570	8,557 Added 50.35%	25,551 $253,000
Q3 2021 Nov 15, 2021	BUY	$7.78 - $10.0 $66,573 - $85,570	8,557 Added 50.35%	25,551 $254,000
Q2 2021 May 17, 2024	SELL	$9.22 - $14.48 $630,620 - $990,388	-68,397 Reduced 80.1%	16,994 $158,000
Q2 2021 Jun 21, 2023	SELL	$9.22 - $14.48 $454,527 - $713,835	-49,298 Reduced 74.36%	16,994 $158,000
Q2 2021 Mar 22, 2023	SELL	$9.22 - $14.48 $237,820 - $373,497	-25,794 Reduced 60.28%	16,994 $158,000
Q2 2021 Aug 16, 2021	BUY	$9.22 - $14.48 $156,684 - $246,073	16,994 New	16,994 $158,000

Others Institutions Holding NUVB

# of Institutions

158

Shares Held

157M

Call Options Held

3.2K

Put Options Held

98.7K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $613M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account

Met Life Investment Management, LLC Nuvation Bio Inc. Transaction History